ENGN

enGene Therapeutics Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. Z4· CIK 0001980845 Biotech & Drug Discovery

$1.56 −0.02 (−1.27%)

Oct 23 4:00 PM ET · prev $1.58

Market cap

$105.9M

Micro cap

Consensus

Buy

56% Buy or better · 18 analysts

Median target

$4.00

+156% · range $2.00–5.00

1 year

−80.4%

from $7.96 · Oct 27

30 days

−20.8%

from $1.97

52-week range

$1.44–12.17

−87% from high · low May 12

Avg volume 20D

819.5K

shares / day

Short interest

🔒 Subscribers only

Insider net

+$10.1K

1 buyer · 0 sellers · 12 mo

Filing reports

analyzed by SecBot

SecBot read MIXED 2 reports · 90 days

Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 1/2

Strongest NEUTRAL enGene reported Q3 2026 results with a net loss of $0.47 per share, which was a 17.5% beat vs the $-0.48…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

A May 8 4 downgrades
R Jun 15 enGene Therapeutics reported Q2 2026 results with a net loss of $0.4…
A Jun 18 Morgan Stanley downgrades
B Sep 22 1 insider buy $10.1K at $1.97

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $10.1K at an average $1.97. No open-market sales. Price is 21% below their cost.
AnalystsBULLISH

10 of 18 rate it Buy or better. Every target is above the price.
EstimatesFALLING

Current-quarter EPS estimate −$0.410 → −$0.458 over 90 days. 2 up, 5 down in 30 days.
TrendDOWNTREND

14% below its 50-day average.

Who's buying

13F

Top holder	Shares	Value
AMERIPRISE FINANCIAL INC	2,675,876	$4.6M
BALYASNY ASSET MANAGEMENT L.P.	1,007,344	$1.7M
MILLENNIUM MANAGEMENT LLC	966,627	$1.7M
RENAISSANCE TECHNOLOGIES LLC	829,700	$1.4M
CITADEL ADVISORS LLC	717,686	$1.2M
UBS Group AG	509,087	$880.7K
JANE STREET GROUP, LLC	382,459	$661.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLP	313,100	$541.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts

Buy 56% rate it Buy or better

Strong Buy4Buy6Hold7Sell1Strong Sell0

12-month targets · 7 analysts

$1.56 $2.00 $4.00 $5.00

Price is below the lowest target. Median implies +156%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Sep 9, 2026	Citizens REITERATE	REITERATE	Market Perform
Sep 8, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Jun 18, 2026	Morgan Stanley DOWNGRADE	DOWNGRADE	Underweight
Jun 16, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
May 14, 2026	UBS MAINTAIN	MAINTAIN	Neutral
May 8, 2026	Citizens DOWNGRADE	DOWNGRADE	Market Perform

Insider ledger

Form 4

$10.1K

bought · 1 insider

sold · 0 insiders

−20.8%

vs their $1.97 cost

Date	Insider	Type	Value
Sep 22, 2026	Grossman William Interim Chief Medical Officer	BUY	$10.1K
Jun 16, 2026	Joustra Wouter Director	AWARD	31,000 sh
Jun 16, 2026	Zoth Lota S. Director	AWARD	31,000 sh
Jun 16, 2026	Heffernan Michael Thomas Director	AWARD	31,000 sh
Jun 16, 2026	HASTINGS PAUL J Director	AWARD	31,000 sh
Jun 16, 2026	Glickman Richard M Director	AWARD	31,000 sh
Jun 16, 2026	Grossman William Interim Chief Medical Officer	AWARD	31,000 sh
Jun 16, 2026	BRUNK GERALD A Director	AWARD	31,000 sh

Earnings setup

Estimates

−$0.46

EPS estimate, this quarter

−12%

estimate change, 90 days

2↑ 5↓

revisions, 30 days

Current-quarter EPS estimate

−$0.410

90d

−$0.410

60d

−$0.458

30d

−$0.458

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.46	-$0.55–-$0.37	+0.0%	$0.00
Next Q	-$0.34	-$0.39–-$0.30	+0.0%	$0.00
Current FY	-$1.81	-$1.89–-$1.71	-0.1%	$0.00
Next FY	-$1.51	-$1.98–-$1.03	-3.9%	$5.6M